Atorvia: A Commercially Focused Biotech
Our approach is to apply a market access & commercial lens early and iteratively throughout the entire development process. Our assets have clear and compelling clinical & commercial opportunities, strong patent protection and clear and determinable pathways to IND, clinical validation, regulatory approval and reimbursement.
Our initial focus is on acute kidney injury, a devastating condition which affects over 70 million patients worldwide and for which there is still no effective therapy. Our science, informed by human rather than animal pathophysiology, targets the regulated cell death process which causes AKI, to prevent and treat this devastating condition. Together with the proprietary diagnostic we are developing, which could revolutionize how AKI is detected, we are advancing our program to pre-clinical stage with a set of solid data already behind us.